Teva wins approval for generic Tamoxifen Citrate Tablets
JERUSALEM, ISRAEL, Feb. 21, 2003 -- Teva Pharmaceutical Industries announced that the FDA has approved the company's ANDAs for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. Shipments will begin immediately.
Tamoxifen Citrate Tablets are the AB-rated generic equivalent of AstraZeneca's Nolvadex Tablets, an anti-estrogen drug for the treatment of breast cancer.
Source: Teva Pharmaceutical Industries
Posted: February 2003